RT info:eu-repo/semantics/article
T1 The time has come for revising the rules of clozapine blood monitoring in Europe. A joint expert statement from the European Clozapine Task Force
A1 Cuevas Castresana, Carlos de las
A1 Verdoux, Hélène
A1 Bittner, Robert A.
A1 Hasan, Alkomiet
A1 Qubad, Mishal
A1 Wagner, Elias
A1 Lepetit, Alexis
A1 Arrojo-Romero, Manuel
A1 Bachmann, Christian
A1 Beex-Oosterhuis, Marieke
A1 Bogers, Jan
A1 Celofiga, Andreja
A1 Cohen, Dan
A1 De Berardis, Domenico
A1 De Hert, Marc
A1 Ebdrup, Bjørn H.
A1 Fountoulakis, Konstantinos N.
A1 Guinart, Daniel
A1 Keating, Dolores
A1 Kopeček, Miloslav
A1 Lally, John
A1 Lazáry, Judit
A1 Luykx, Jurjen J.
A1 Maronas Amigo, Olalla
A1 Molden, Espen
A1 Nielsen, Jimmi
A1 O’Donoghue, Brian
A1 Oswald, Pierre
A1 Radulescu, Flavian S.
A1 Rohde, Christopher
A1 Sagud, Marina
A1 Sanz Álvarez, Emilio José
A1 Šimunović Filipčić, Ivona
A1 Sommer, Iris E.
A1 Taipale, Heidi
A1 Tiihonen, Jari
A1 Tuppurainen, Heli
A1 Veerman, Selene
A1 Wilkowska, Alina
A1 Spina, Edoardo
A1 Schulte, Peter
A2 Medicina InternaDermatología y Psiquiatría
A2 IUNEGrupo de Adherencia Terapéutica
AB The European Clozapine Task Force is a group of psychiatrists and pharmacologists practicing in 18 countries under European Medicines Agency (EMA) regulation, who are deeply concerned about the underuse of clozapine in European countries. Although clozapine is the most effective antipsychotic for people with treatment-resistant schizophrenia, a large proportion of them do not have access to this treatment. Concerns about clozapine-induced agranulocytosis and stringent blood monitoring rules are major barriers to clozapine prescribing and use. There is a growing body of evidence that the incidence of clozapine-induced agranulocytosis is very low after the first year of treatment. Maintaining lifelong monthly blood monitoring after this period contributes to unjustified discontinuation of clozapine. Weleverage recent and replicated evidence on the long-term safety of clozapine to call for the revision and updating of the EMA’s blood monitoringrules,thusaimingtoovercomethismajorbarriertoclozapineprescribinganduse.Webelievethetimehascomeforrelaxingthe rules without increasing the risks for people using clozapine in Europe.
YR 2025
FD 2025
LK http://riull.ull.es/xmlui/handle/915/41303
UL http://riull.ull.es/xmlui/handle/915/41303
LA en
DS Repositorio institucional de la Universidad de La Laguna
RD 12-may-2025